Jan Garfinkle founded Arboretum Ventures in 2002 and is a Managing Director.
Jan targets promising medical device and diagnostic technologies that enable meaningful healthcare system savings. Her expertise in medical technology stems from leadership roles she held at two important cardiovascular start-ups that spurred the market for catheter-based interventions. While at Arboretum, Jan has led investments and held board seats in more than a dozen portfolio companies. In addition to several other exits, Jan led Arboretum’s investment in HandyLab and served on the Board of Directors for five years until the company was acquired by BD in 2009 for $275 million. She also led the Series A investment into Esperion Therapeutics which subsequently went public and has a market cap over $2 billion on the NASDAQ.
Jan spent 20 years in senior management positions within entrepreneurial healthcare companies. Prior to founding Arboretum, she worked for two successful medical device start-up companies, Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI). Each of these companies was acquired by Eli Lilly for more than $100 million and became the foundation for Guidant Corporation. She joined each company early in its development and held key management roles in marketing, clinical research, and sales. After Guidant, she was Founder and President of Strategic Marketing Consultants, focused on early-stage healthcare companies in the Midwest. Jan began her career as a manufacturing engineer and production line manager for Procter and Gamble.
Fund's investment verticals: medical devices, medical diagnostics, healthcare technology, technology based healthcare services and life sciences.